SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma

Cell Cycle

Volumn 14, Issue 9, 2015, Pages 1389-1402

  Coda, Davide Martino ^a,b,f   Lingua, Marcello Francesco ^a,b   Morena, Deborah ^a,b   Foglizzo, Valentina ^a,b,c   Bersani, Francesca ^a,b,d   Ala, Ugo ^e   Ponzetto, Carola ^a,b   Taulli, Riccardo ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CERMS   (Italy)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TURIN   (Italy)

^f IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Differentiation therapy; Metabolism and cancer; MiR 206; Rhabdomyosarcoma

Indexed keywords

AGAR; DICHLOROACETIC ACID; DOXYCYCLINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HISTONE H3; HISTONE METHYLTRANSFERASE; MICRORNA; MICRORNA 206; PYRUVATE DEHYDROGENASE; PYRUVIC ACID; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; MIRN206 MICRORNA, HUMAN; MIRN206 MICRORNA, MOUSE; MUSCLE PROTEIN; SMYD1 PROTEIN, HUMAN; SMYD1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME REACTIVATION; EPIGENETICS; GENE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC REGULATION; HUMAN; HUMAN TISSUE; METABOLISM; MICROARRAY ANALYSIS; MITOCHONDRION; MOLECULAR BIOLOGY; MUSCLE CELL; PHENOTYPE; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SMYD1 GENE; CELL TRANSFORMATION; DRUG EFFECTS; ENERGY METABOLISM; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; MUSCLE DEVELOPMENT; MYOBLAST; PATHOLOGY; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE CELL; TIME FACTOR; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DICHLOROACETIC ACID; DNA-BINDING PROTEINS; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSEPHOSPHATE DEHYDROGENASE; HUMANS; MICRORNAS; MUSCLE DEVELOPMENT; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MYOBLASTS; PHENOTYPE; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84983542682     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1005993     Document Type: Article

References (64)

1. Merlino G, Helman LJ. Rhabdomyosarcoma-working out the pathways. Oncogene 1999; 18: 5340-8; PMID: 10498887; http://dx.doi.org/10.1038/sj. onc.1203038
2. Belyea B, Kephart JG, Blum J, Kirsch DG, Linardic CM. Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Sarcoma 2012; 2012: 406239; PMID: 22619564; http://dx.doi.org/10.1155/2012/406239
3. Keller C, Guttridge DC. Mechanisms of impaired differentiation in rhabdomyosarcoma. FEBS J 2013; 280: 4323-34; PMID: 23822136; http://dx.doi.org/10.1111/febs.12421
4. McCarthy JJ. MicroRNA-206: the skeletal muscle-specific myomiR. Biochim Biophys Acta 2008; 1779: 682-91; PMID: 18381085; http://dx.doi.org/10.1016/j. bbagrm.2008.03.001
5. Kim HK, Lee YS, Sivaprasad U, Malhotra A, Dutta A. Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol 2006; 174: 677-87; PMID: 16923828; http://dx.doi.org/10.1083/jcb.200603008
6. Goljanek-Whysall K, Sweetman D, M€unsterberg AE. microRNAs in skeletal muscle differentiation and disease. Clin Sci 2012; 123: 611-25; PMID: 22888971; http://dx.doi.org/10.1042/CS20110634
7. Goljanek-Whysall K, Pais H, Rathjen T, Sweetman D, Dalmay T, M€unsterberg A. Regulation of multiple target genes by miR-1 and miR-206 is pivotal for C2C12 myoblast differentiation. J Cell Sci 2012; 125: 3590-600; PMID: 22595520; http://dx.doi.org/10.1242/ jcs.101758
8. Lin C-Y, Lee H-C, Fu C-Y, Ding Y-Y, Chen J-S, Lee M-H, Huang W-J, Tsai H-J. MiR-1 and miR-206 target different genes to have opposing roles during angiogenesis in zebrafish embryos. Nat Commun 2013; 4: 2829; PMID: 24264597
9. Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M, Tuschl T, Ponzetto C. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 2009; 119: 2366-78; PMID: 19620785
10. Lee M-H, Jothi M, Gudkov AV, Mal AK. Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state. Cancer Res 2011; 71: 3921-31; PMID: 21493592; http://dx.doi.org/10.1158/0008-5472.CAN-10-3358
11. MacQuarrie KL, Tapscott SJ. Stuck in a balancing act: histone methyltransferase activity of KMT1A traps alveolar rhabdomyosarcomas in an undifferentiated state. Cell Cycle 2011; 10: 3225-6; PMID: 21941084; http://dx.doi.org/10.4161/cc.10.19.17451
12. Macquarrie KL, Yao Z, Young JM, Cao Y, Tapscott SJ. miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells. Skelet Muscle 2012; 2: 7; PMID: 22541669; http://dx.doi.org/10.1186/2044-5040-2-7
13. Alteri A, De Vito F, Messina G, Pompili M, Calconi A, Visca P, Mottolese M, Presutti C, Grossi M. Cyclin D1 is a major target of miR-206 in cell differentiation and transformation. Cell Cycle 2013; 12: 3781-90; PMID: 24107628; http://dx.doi.org/10.4161/cc.26674
14. Elliman SJ, Howley BV, Mehta DS, Fearnhead HO, Kemp DM, Barkley LR. Selective repression of the oncogene cyclin D1 by the tumor suppressor miR-206 in cancers. Oncogenesis 2014; 3:e113; PMID: 25111862; http://dx.doi.org/10.1038/oncsis.2014.26
15. Li L, Sarver AL, Alamgir S, Subramanian S. Downregulation of microRNAs miR-1,-206 and-29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. Lab Investig 2012; 92: 571-83; PMID: 22330340; http://dx.doi.org/10.1038/labinvest.2012.10
16. Yan D, Dong XDE, Chen X, Wang L, Lu C, Wang J, Qu J, Tu L. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 2009; 284: 29596-604; PMID: 19710019; http://dx. doi.org/10.1074/jbc.M109.020511
17. Boutet SC, Cheung TH, Quach NL, Liu L, Prescott SL, Edalati A, Iori K, Rando TA. Alternative polyadenylation mediates microRNA regulation of muscle stem cell function. Cell Stem Cell 2012; 10: 327-36; PMID: 22385659; http://dx.doi.org/10.1016/j. stem.2012.01.017
18. Dey BK, Gagan J, Dutta A. miR-206 and-486 induce myoblast differentiation by downregulating Pax7. Mol Cell Biol 2011; 31: 203-14; PMID: 21041476; http:// dx.doi.org/10.1128/MCB.01009-10
19. Lu L, Zhou L, Chen EZ, Sun K, Jiang P, Wang L, Su X, Sun H, Wang H. A Novel YY1-miR-1 regulatory circuit in skeletal myogenesis revealed by genome-wide prediction of YY1-miRNA network. PloS One 2012; 7: e27596; PMID: 22319554; http://dx.doi.org/10.1371/ journal.pone.0027596
20. Chen J-F, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang D-Z. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006; 38: 228-33; PMID: 16380711; http://dx.doi.org/10.1038/ng1725
21. Winbanks CE, Wang B, Beyer C, Koh P, White L, Kantharidis P, Gregorevic P. TGF-beta regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. J Biol Chem 2011; 286: 13805-14; PMID: 21324893; http://dx.doi.org/10.1074/jbc.M110.192625
22. Soleimani VD, Yin H, Jahani-Asl A, Ming H, Kockx CEM, van Ijcken WFJ, Grosveld F, Rudnicki MA. Snail regulates MyoD binding-site occupancy to direct enhancer switching and differentiation-specific transcription in myogenesis. Mol Cell 2012; 47: 457-68; PMID: 22771117; http://dx.doi.org/10.1016/j.molcel.2012.05.046
23. Song G, Zhang Y, Wang L. MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem 2009; 284: 31921-7; PMID: 19723635; http://dx.doi.org/10.1074/jbc.M109.046862
24. Taulli R, Foglizzo V, Morena D, Coda DM, Ala U, Bersani F, Maestro N, Ponzetto C. Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma. Oncogene 2014; 33: 2354-62; PMID: 23728344; http://dx.doi.org/10.1038/onc.2013.188
25. Dillon SC, Zhang X, Trievel RC, Cheng X. The SETdomain protein superfamily: protein lysine methyltransferases. Genome Biol 2005; 6: 227; PMID: 16086857; http://dx.doi.org/10.1186/gb-2005-6-8-227
26. Tan X, Rotllant J, Li H, De Deyne P, DeDeyne P, Du SJ. SmyD1, a histone methyltransferase, is required for myofibril organization and muscle contraction in zebrafish embryos. Proc Natl Acad Sci 2006; 103: 2713-8; PMID: 16477022; http://dx.doi.org/10.1073/pnas.0509503103
27. Sims RJ, Weihe EK, Zhu L, O’Malley S, Harriss JV, Gottlieb PD. m-Bop, a repressor protein essential for cardiogenesis, interacts with skNAC, a heart-and muscle-specific transcription factor. J Biol Chem 2002; 277: 26524-9; PMID: 12011100; http://dx.doi.org/10.1074/jbc.M204121200
28. Gottlieb PD, Pierce SA, Sims RJ, Yamagishi H, Weihe EK, Harriss JV, Maika SD, Kuziel WA, King HL, Olson EN, et al. Bop encodes a musclerestricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis. Nat Genet 2002; 31: 25-32; PMID: 11923873
29. Park CY, Pierce SA, von Drehle M, Ivey KN, Morgan JA, Blau HM, Srivastava D. skNAC, a Smyd1-interacting transcription factor, is involved in cardiac development and skeletal muscle growth and regeneration. Proc Natl Acad Sci 2010; 107: 20750-5; PMID: 21071677; http://dx.doi.org/10.1073/ pnas.1013493107
30. Li D, Niu Z, Yu W, Qian Y, Wang Q, Li Q, Yi Z, Luo J, Wu X, Wang Y, et al. SMYD1, the myogenic activator, is a direct target of serum response factor and myogenin. Nucleic Acids Res 2009; 37: 7059-71; PMID: 19783823; http://dx.doi.org/10.1093/nar/ gkp773
31. Just S, Meder B, Berger IM, Etard C, Trano N, Patzel E, Hassel D, Marquart S, Dahme T, Vogel B, et al. The myosin-interacting protein SMYD1 is essential for sarcomere organization. J Cell Sci 2011; 124: 3127-36; PMID: 21852424; http://dx.doi.org/10.1242/ jcs.084772
32. Berkholz J, Michalick L, Munz B. The E3 SUMO ligase Nse2 regulates sumoylation and nuclear-to-cytoplasmic translocation of skNAC-Smyd1 in myogenesis. J Cell Sci 2014; 127: 3794-804; PMID: 25002400; http://dx.doi.org/10.1242/jcs.150334
33. Li H, Xu J, Bian Y-H, Rotllant P, Shen T, Chu W, Zhang J, Schneider M, Du SJ. Smyd1b_tv1, a key regulator of sarcomere assembly, is localized on the M-line of skeletal muscle fibers. PloS One 2011; 6:e28524; PMID: 22174829; http://dx.doi.org/10.1371/journal. pone.0028524
34. Li H, Zhong Y, Wang Z, Gao J, Xu J, Chu W, Zhang J, Fang S, Du SJ. Smyd1b is required for skeletal and cardiac muscle function in zebrafish. Mol Biol Cell 2013; 24: 3511-21; PMID: 24068325; http://dx.doi. org/10.1091/mbc.E13-06-0352
35. Stanton RC. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life 2012; 64: 362-9; PMID: 22431005; http://dx.doi.org/10.1002/ iub.1017
36. Jones NP, Schulze A. Targeting cancer metabolism-aiming at a tumour’s sweet-spot. Drug Discov Today 2012; 17: 232-41; PMID: 22207221; http://dx.doi.org/10.1016/j.drudis.2011.12.017
37. Kuo W, Lin J, Tang TK. Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. Int J Cancer 2000; 85: 857-64; PMID: 10709108; http://dx.doi.org/10.1002/(SICI)1097-0215(20000315)85: 6%3c857:: AID-IJC20%3e3.0.CO;2-U
38. Du W, Jiang P, Mancuso A, Stonestrom A, Brewer MD, Minn AJ, Mak TW, Wu M, Yang X. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat Cell Biol 2013; 15: 991-1000; PMID: 23811687; http://dx.doi.org/10.1038/ncb2789
39. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, Yang X. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 2011; 13: 310-6; PMID: 21336310; http://dx. doi.org/10.1038/ncb2172
40. Schwartz AG, Pashko LL. Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. J Cell Biochem Suppl 1995; 22: 210-7; PMID: 8538200; http://dx.doi.org/10.1002/jcb.240590826
41. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99: 989-94; PMID: 18766181; http://dx.doi.org/10.1038/sj. bjc.6604554
42. Williamson D, Missiaglia E, de Reyniès A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Laè M, Frèneaux P, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010; 28: 2151-8; PMID: 20351326; http://dx. doi.org/10.1200/JCO.2009.26.3814
43. Walters ZS, Villarejo-Balcells B, Olmos D, Buist TWS, Missiaglia E, Allen R, Al-Lazikani B, Garrett MD, Blagg J, Shipley J. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene 2013; 33: 1148-57; PMID: 23435416; http://dx.doi. org/10.1038/onc.2013.46
44. Weintraub H, Tapscott SJ, Davis RL, Thayer MJ, Adam MA, Lassar AB, Miller AD. Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. Proc Natl Acad Sci 1989; 86: 5434-8; PMID: 2748593; http://dx. doi.org/10.1073/pnas.86.14.5434
45. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, Maguire C, Gammer T-L, Mackey JR, Fulton D, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010; 2: 31ra34; PMID: 20463368
46. Dunbar EM, Coats BS, Shroads AL, Langaee T, Lew A, Forder JR, Shuster JJ, Wagner DA, Stacpoole PW. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest New Drugs 2014; 32: 452-64; PMID: 24297161; http://dx.doi.org/10.1007/s10637-013-0047-4
47. Taulli R, Bersani F, Ponzetto C. Micro-orchestrating differentiation in cancer. Cell Cycle 2010; 9: 918-22; PMID: 20160508; http://dx.doi.org/10.4161/ cc.9.5.10864
48. Rota R, Ciarapica R, Giordano A, Miele L, Locatelli F. MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality. Mol Cancer 2011; 10: 120; PMID: 21943149; http://dx.doi.org/10.1186/1476-4598-10-120
49. Cieśla M, Dulak J, Józkowicz A. MicroRNAs and epigenetic mechanisms of rhabdomyosarcoma development. Int J Biochem Cell Biol 2014; 53C: 482-92; http://dx.doi.org/10.1016/j.biocel.2014.05.003
50. Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev 2002; 12: 198-209; PMID: 11893494; http://dx.doi.org/10.1016/S0959-437X(02)00287-3
51. Mal AK. Histone methyltransferase Suv39h1 represses MyoD-stimulated myogenic differentiation. EMBO J 2006; 25: 3323-34; PMID: 16858404; http://dx.doi. org/10.1038/sj.emboj.7601229
52. Gillespie MA, Le Grand F, Scimè A, Kuang S, von Maltzahn J, Seale V, Cuenda A, Ranish JA, Rudnicki MA. p38-{gamma}-dependent gene silencing restricts entry into the myogenic differentiation program. J Cell Biol 2009; 187: 991-1005; PMID: 20026657; http://dx. doi.org/10.1083/jcb.200907037
53. Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev 2004; 18: 2627-38; PMID: 15520282; http://dx.doi.org/10.1101/gad.1241904
54. Pasini D, Cloos PAC, Walfridsson J, Olsson L, Bukowski J-P, Johansen JV, BakM, Tommerup N, Rappsilber J, Helin K. JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. Nature 2010; 464: 306-10; PMID: 20075857; http://dx.doi. org/10.1038/nature08788
55. Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R, Giordano A. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle 2009; 8: 172-5; PMID: 19106613; http://dx.doi. org/10.4161/cc.8.1.7292
56. Barski A, Cuddapah S, Cui K, Roh T-Y, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-Resolution Profiling of Histone Methylations in the Human Genome. Cell 2007; 129: 823-37; PMID: 17512414; http://dx.doi.org/10.1016/j.cell.2007.05.009
57. Tao Y, Neppl RL, Huang Z-P, Chen J, Tang R-H, Cao R, Zhang Y, Jin S-W, Wang D-Z. The histone methyltransferase Set7/9 promotes myoblast differentiation and myofibril assembly. J Cell Biol 2011; 194: 551-65; PMID: 21859860; http://dx.doi.org/10.1083/jcb.201010090
58. Sirinupong N, Brunzelle J, Ye J, Pirzada A, Nico L, Yang Z. Crystal structure of cardiac-specific histone methyltransferase SmyD1 reveals unusual active site architecture. J Biol Chem 2010; 285: 40635-44; PMID: 20943667; http://dx.doi.org/10.1074/jbc.M110.168187
59. Berkholz J, Kuzyniak W, Hoepfner M, Munz B. Overexpression of the skNAC gene in human rhabdomyosarcoma cells enhances their differentiation potential and inhibits tumor cell growth and spreading. Clin Exp Metastasis 2014; 31: 869-79; PMID: 25209525; http:// dx.doi.org/10.1007/s10585-014-9676-z
60. Vander Heiden MG, Lunt SY, Dayton TL, Fiske BP, Israelsen WJ, Mattaini KR, Vokes NI, Stephanopoulos G, Cantley LC, Metallo CM, et al. Metabolic pathway alterations that support cell proliferation. Cold Spring Harb Symp Quant Biol 2011; 76: 325-34; PMID: 22262476; http://dx.doi.org/10.1101/ sqb.2012.76.010900
61. Cacchiarelli D, Martone J, Girardi E, Cesana M, Incitti T, Morlando M, Nicoletti C, Santini T, Sthandier O, Barberi L, et al. MicroRNAs involved in molecular circuitries relevant for the duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab 2010; 12: 341-51; PMID: 20727829; http://dx.doi.org/10.1016/j. cmet.2010.07.008
62. Schwartz AG, Pashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev 2004; 3: 171-87; PMID: 15177053; http://dx.doi.org/10.1016/j.arr.2003.05.001
63. Lembo A, Di Cunto F, Provero P. Shortening of 30UTRs correlates with poor prognosis in breast and lung cancer. PloS One 2012; 7:e31129; PMID: 22347440; http://dx.doi.org/10.1371/journal. pone.0031129
64. Polimeni M, Voena C, Kopecka J, Riganti C, Pescarmona G, Bosia A, Ghigo D. Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochem J 2011; 439: 141-9; PMID: 21679161; http://dx.doi.org/10.1042/ BJ20102016